<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03608618</url>
  </required_header>
  <id_info>
    <org_study_id>CP-M11-101</org_study_id>
    <nct_id>NCT03608618</nct_id>
  </id_info>
  <brief_title>Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma</brief_title>
  <official_title>A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaxCyte, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI Clinical Trial and Consulting Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MaxCyte, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 dose escalation study to characterize the feasibility, safety and
      tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly
      doses for women with platinum resistant high grade serous adenocarcinoma of the ovary,
      primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with
      recurrence after prior chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events as assessed by CTCAE v.5.0</measure>
    <time_frame>6 weeks</time_frame>
    <description>number and severity of adverse events according to NCI CTCAE v.5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>6 weeks</time_frame>
    <description>tumor response scored by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)</measure>
    <time_frame>6 weeks</time_frame>
    <description>tumor response scored by irRECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Peritoneal Mesothelioma</condition>
  <condition>Fallopian Tube Adenocarcinoma</condition>
  <condition>Adenocarcinoma of the Ovary</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCY-M11</intervention_name>
    <description>Intraperitoneal administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be able to undergo peripheral blood leukapheresis; have successful placement of an
             intraperitoneal catheter

          -  Be diagnosed with one of the following: metastatic or unresectable high grade serous
             adenocarcinoma involving the ovary, primary peritoneum, or fallopian tube with
             peritoneal involvement, not including mixed histologies, OR unresectable epithelioid
             or biphasic peritoneal mesothelioma

          -  Be at least 4 weeks from previous anti-cancer therapy

          -  Have a life expectancy of greater than 3 months.

        Exclusion Criteria:

          -  Females who are pregnant, trying to become pregnant, or breastfeeding

          -  Diagnosis of HIV or chronic active Hepatitis B or C

          -  Symptomatic or uncontrolled brain metastases requiring current treatment

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Lack of recovery of prior mild adverse events due to earlier therapies

          -  Active infection

          -  Another previous or current malignancy within the last 3 years, with exceptions

          -  Concomitant chronic use of steroids or NSAIDs

          -  Concomitant use of complementary or alternative medication or therapy

          -  Autoimmune disease or inflammatory disease within previous 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Dansky Ullmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>MaxCyte, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Dansky Ullmann, MD</last_name>
    <phone>617-806-6190</phone>
    <email>cdanskyullmann@maxcyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Pennella, MD</last_name>
    <phone>301-798-6591</phone>
    <email>epennella@maxcyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute, National Institutes of Health</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Annunziata, MD, PhD</last_name>
      <phone>888-624-1937</phone>
      <email>annunzic@mail.nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Boyle</last_name>
      <phone>240-760-6006</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington University at St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Premal Thaker, MD</last_name>
      <phone>800-856-7196</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platinum resistant</keyword>
  <keyword>high grade serous adenocarcinoma</keyword>
  <keyword>recurrence after chemotherapy</keyword>
  <keyword>intraperitoneal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

